October 13, 2022 — Proscia, a leading provider of digital and computational pathology solutions, has introduced the next version of its Concentriq Dx platform for primary diagnostic workflows, which is CE-marked under IVDR*. The release brings together new features and a compelling user experience to help even the largest laboratory networks transition to 100% digital diagnosis. In doing so, they can realize the full promise of the shift away from microscope-based pathology.
A recent analysis of the 2021 College of American Pathologists Practice Leader Survey indicates that only 65% of practices looking to hire pathologists could fill all open positions, marking a decline from 2017.[1] This finding suggests a worsening shortage of available pathologists at a time when the global cancer burden is expected to rise. According to a 2022 report from KLAS Research, 96% of providers that use digital pathology are realizing quality gains, and 80% are seeing time savings.[2] To scale their implementations and increasingly fulfill their commitments to excellent patient care, they need an enterprise-grade platform that accelerates all aspects of the pathologist’s day.
“Digitization is one of the solutions to the systemic challenges plaguing the practice of pathology today,” said Michael Feldman, MD, Ph.D., Vice Chair for Clinical Services, Department of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania. “Proscia understands what laboratories need to drive full-scale adoption.”
Available today, the expanded Concentriq Dx raises the bar for modern diagnostic pathology with new features and enhancements including:
- An inviting user experience that engages pathologists. The platform’s compelling interface draws pathologists into a robust digital environment that extends the intuitiveness of the microscope across the end-to-end workflow. By enabling pathologists to work with speed and ease, the updated Concentriq Dx can drive powerful efficiencies that may help to reduce burnout and attract new talent.
- Collaboration mode for driving higher quality services. Laboratories can now seamlessly access sub-specialist expertise to deliver faster, more informed results to patients. The new version enables peer reviews, conferencing, consults, and tumor boards, as well as enhanced live collaboration, to connect multi-site and remote teams as if they were all practicing from one location.
- An enterprise administration module enabling multi-site networks to scale more rapidly. Concentriq Dx now puts even more control into the hands of laboratory administrators with sophisticated configurability to empower users. Flexible roles and permissions and site-specific settings ensure that the platform will continue to meet current and future needs.
“Achieving full digitization requires a platform that provides end-to-end functionality, an effortless user experience, and scalability,” said Dr. Alexi Baidoshvili, Clinical Pathologist at LabPON, the first laboratory in the world to reach 100% digital pathology diagnosis.[3] “Concentriq Dx is the only platform I’ve seen that successfully delivers on all three of these pillars.”
Trusted by top laboratories and health systems, Concentriq Dx is a secure, AI-ready digital pathology platform that powers primary diagnostic workflows. It offers best-of-breed interoperability with leading scanners, laboratory information systems, and image analysis applications to centralize pathology data and operations for growing technology ecosystems. The platform can also be rapidly deployed on existing IT infrastructure.
“We are at the tipping point of the next wave of digital pathology adoption,” said Nathan Buchbinder, Proscia’s Chief Product Officer. “Our team set out to create a new standard of modern diagnostic pathology with this release. We built it working closely with digital pathology pioneers to give our customers the missing pieces needed to improve patient care during these increasingly challenging times.”
For more information: www.proscia.com
*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency.
January 22, 2026 
